This product is an immunomodulatory drug. It has the function of regulating and enhancing the cellular immune function of the human body. It can promote the maturation of T lymphocytes in the peripheral blood after mitogen activation, increase the secretion of various lymphokines (such as α, γ interferon, interleukin 2 and interleukin 3) after T cells are activated by various antigens or mitogens, and increase the level of lymphokine receptors on T cells. It also enhances the response of lymphocytes by activating T4 helper cells. In addition, this product may affect the chemotaxis of NK precursor cells, which become more cytotoxic after exposure to interferon. Therefore, this product has the function of regulating and enhancing the cellular immune function of the human body. This product is an immune bidirectional modulator. It has the function of inducing and promoting the differentiation, maturation and activation of T lymphocytes and their subsets, regulating T lymphocytes.

A coenzyme for acetylation reactions in the body. It participates in acetylation reactions in the body and plays an important role in the metabolism of sugar, fat and protein, such as the tricarboxylic acid cycle, liver glycogen storage, acetylcholine synthesis, lowering cholesterol, regulating blood lipid content and synthesizing steroid substances.

It acts directly on the endogenous fibrinolytic system and can catalyze the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. It has a fast onset and good effect on newly formed thrombi. It can also increase the activity of vascular ADP enzyme, inhibit ADP-induced platelet aggregation, and prevent thrombosis. After intravenous infusion, the activity of plasmin in the patient's body is significantly increased; a few hours after stopping the drug, the plasmin activity returns to the original level. However, the decrease in plasma fibrin or fibrinogen levels and the increase in their degradation products can last for 12-24 hours. It shows that the thrombolytic effect is significantly correlated with the drug dose and the time window of administration.

This product directly acts on the endogenous fibrinolytic system, catalyzing the cleavage of plasminogen into plasmin, which can not only degrade fibrin clots, but also degrade fibrinogen, coagulation factor V and coagulation factor VIII in the blood circulation, thereby exerting a thrombolytic effect. This product has a fast onset and good effect on newly formed thrombi. This product can also increase the activity of vascular ADP enzyme, inhibit ADP-induced platelet aggregation, and prevent thrombosis.